


Product Name : Flumbatinib
Cat. No. : PC-38393
CAS No. : 895519-90-1
Molecular Formula : C₂₉H₂₉F₃N₈O
Molecular Weight : 562.601
Target : Bcr-Abl
Solubility : 10 mM in DMSO



Biological Activity

Flumatinib (HH-GV678) is a potent **BCR-ABL/PDGFR/KIT** inhibitor, potently inhibits ABL, PDGFR- β and KIT kinase with IC₅₀ of 1.2, 307.6 and 665.5 nM, respectively.

Flumatinib (HH-GV678) displays only weak inhibition of VEGFR2/3, SRC, FLT3, RET, EGFR, and HER2.

Flumatinib (HH-GV678) is a more potent inhibitor of BCR-ABL1 tyrosine kinase than imatinib (IC₅₀=100.9 nM).

Flumatinib (HH-GV678) exhibited a selective inhibition pattern toward imatinib-resistant KIT mutants associated with GISTs, effectively overcame the drug resistance of certain KIT mutants with activation loop mutations (i.e., D820G, N822K, Y823D, and A829P).

Flumatinib (HH-GV678) had superior efficacy compared with imatinib or sunitinib against 32D cells with the secondary mutation Y823D.

References

- Luo H, et al. *Leukemia*. 2010 Oct;24(10):1807-9.
 Kuang Y, et al. *Cancer Chemother Pharmacol*. 2020 Sep;86(3):339-346.
 Zhang L, et al. *Clin Cancer Res*. 2021 Jan 1;27(1):70-77.
 Zhao J, et al. *Cancer Sci*. 2014 Jan;105(1):117-25.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com